What Is Ibogaine? Trump Admin Fast-Tracks Psychoactive Drug for Approval
Summary
The Trump administration is working to speed up approval and research of ibogaine, a powerful psychedelic drug from Africa. Ibogaine shows promise in treating addiction and mental health problems but carries some health risks. President Trump signed an executive order to help fast-track psychedelic therapies, including ibogaine, especially to benefit veterans and people with hard-to-treat conditions.Key Facts
- Ibogaine is a natural psychoactive compound from the Tabernanthe iboga shrub found in Central and West Africa.
- It has been traditionally used in spiritual ceremonies and is now studied for addiction, PTSD, and depression treatment.
- Ibogaine may reduce cravings and withdrawal symptoms after just one session, acting as a “pattern interrupter.”
- The drug’s effects last over 30 hours and can help the brain change addiction-related pathways.
- Researchers caution that more large studies are needed, and ibogaine has serious safety risks, like heart problems.
- In April, President Trump signed an order directing federal agencies to speed up research and approval of psychedelic medicines.
- The order includes $50 million to support state-level psychedelic therapy research.
- Veterans’ groups and some public figures support the effort, while there are concerns about moving too fast without enough science.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
